TUDER JEFFREY 4
4 · Hyperliquid Strategies Inc · Filed Dec 12, 2025
Insider Transaction Report
Form 4
TUDER JEFFREY
Director
Transactions
- Other
Common Stock
2025-12-02+8,188→ 8,188 total(indirect: See Footnote) - Other
Warrants
2025-12-02+16,000→ 16,000 total(indirect: See Footnote)Exercise: $6.25From: 2025-12-02Exp: 2025-07-14→ Common Stock (16,000 underlying)
Footnotes (3)
- [F1]On December 2, 2025, Hyperliquid Strategies Inc (the "Company") completed its previously announced business combination (the "Closing"), pursuant to the Business Combination Agreement, dated as of July 11, 2025 (as amended on September 22, 2025, the "BCA"), by and among the Company, Sonnet BioTherapeutics Holdings, Inc. ("Sonnet"), Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC . In connection with the Closing, Tremson Capital Management, LLC ("Tremson") received 8,188 shares of common stock, par value $0.01 per share, of the Company (the "Common Stock"), in exchange of certain securities of Sonnet Tremson held prior to the Closing.
- [F2]The securities are held directly by Tremson and indirectly by Jeffrey Tuder, managing member of Tremson. Mr. Tuder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F3]In connection with the Closing, Tremson received warrants to purchase an aggregate of 16,000 shares of Common Stock, at an initial exercise price of $6.25 per share, in exchange of certain warrants of Sonnet Tremson held prior to the Closing.